Professor of medical ethics in medicine in the Division of Medical Ethics at Weill Cornell Medicine.
Ethics Hum Res. 2023 Mar;45(2):2-13. doi: 10.1002/eahr.500157.
The growing commercialization of science has raised concerns about financial conflicts of interest (COIs). Evidence suggests that such conflicts threaten the integrity of research and the well-being of research participants. Trying to minimize these negative effects, federal agencies, academic institutions, and publishers have developed conflict-of-interest policies. Among such policies, recommendations or requirements to disclose financial COIs to potential research participants and patients have become commonplace. Here, I argue that disclosing conflicts of interest to potential research participants fails to achieve the weighty moral goals that presumably ground such policies. This is so either because disclosure is simply a wrong means for achieving some of the goals in question or because, although disclosure could be an appropriate means for some of those goals, the way in which it is implemented prevents fulfillment of the desirable moral aim.
科学的商业化日益发展,引发了人们对利益冲突(COI)的关注。有证据表明,这种冲突会威胁到研究的完整性和研究参与者的福祉。为了尽量减少这些负面影响,联邦机构、学术机构和出版商制定了利益冲突政策。在这些政策中,向潜在的研究参与者和患者披露财务利益冲突的建议或要求已变得很普遍。在这里,我认为向潜在的研究参与者披露利益冲突并不能实现这些政策所依据的重要道德目标。这要么是因为披露本身只是实现某些目标的错误手段,要么是因为尽管披露可能是实现其中一些目标的适当手段,但披露的实施方式阻碍了理想道德目标的实现。